CJC-1295 / Ipamorelin Blend

The catalogue line is CJC-1295 (no DAC) 5mg + Ipamorelin 5mg: two sequences co-lyophilised in one sealed vial, ordered as one SKU and documented as one unit. Standalone Ipamorelin 5mg is a separate lot family. A method that requires a certificate describing only CJC-1295 is still not served by this blend.

The no-DAC qualifier is the part of the name that does procurement work. CJC-1295 circulates under one name in two forms, and the CJC-1295 monograph sets out why: the DAC version carries a reactive linker that binds albumin covalently, the no-DAC version omits it and is in practice modified GRF(1-29). They differ in mass and in chromatographic behaviour. A requisition reading only CJC-1295 5mg is under-specified, and the mismatch usually surfaces when a certificate meets a method written for the other form.

The second sequence is a designed pentapeptide rather than a fragment of anything. As the ipamorelin monograph describes, it contains alpha-aminoisobutyric acid and two D-configured residues with a C-terminal amide, which makes it resistant to the proteases that recognise natural L-peptides and also means generic peptide assumptions do not transfer to it cleanly.

A blend of this kind exists because the components are mechanistically unlike each other. The CJC-1295 component is an analogue of growth hormone-releasing hormone and acts at the GHRH receptor. The ipamorelin component is an agonist at GHS-R1a, the receptor for endogenous ghrelin. Two separate receptor populations, two separate signalling routes into the same axis — that complementarity, not convenience, is the reason the pairing appears in research supply at all.

The literature behind each half is separate and was generated on each sequence alone. Teichman and colleagues reported prolonged stimulation of growth hormone and IGF-I secretion after administration of CJC-1295 in adults, and Ionescu and Frohman reported that pulsatile secretion persisted during continuous stimulation by the same analogue. Raun and colleagues characterised ipamorelin as selective relative to earlier secretagogues in its class.

None of that work used this combination. Adding findings from two independent literatures together and presenting the sum as a description of the blend is not a sound inference, and VaultLabs makes no claim of its own about what the mixture does.

Once two sequences have been filled together, the thing in the vial is a new lot with its own identifier and its own certificate. The component materials that went into it no longer exist as separate catalogue items, so a certificate describing one of them describes something the laboratory does not have. Ratio and content are properties of the blend lot and can only be established on the blend lot.

This is also why lot records never cross catalogue lines. A record published for this blend cannot release a single-sequence SKU, and no single-sequence record can release this one. Per-lot certificates appear at batch verification and are indexed at the product COA record once uploaded. Each shipment includes a Certificate of Analysis and a traceable lot number, and where analytical release is complete the published record can be matched against the number printed on the label. If the lot in hand has no published record yet, raise a documentation request with the lot and order reference.

A single area-percent figure means something different here than on a single-sequence vial. On one sequence, main-peak area against total area is a statement about how much of the material is the intended substance. On a two-component fill, the two intended sequences are separate peaks, so the same arithmetic applied naively makes each component look like an impurity in the other.

The questions worth asking of a blend record are therefore different: are both named sequences separately identified, by what method, and does the record state the relationship between them rather than a single headline number? Mass analysis carries more weight than usual for this line, because it is the most direct way to confirm that the CJC-1295 component is the no-DAC form and not the DAC-conjugated one. Field-by-field guidance is in how to read a peptide COA, and the blend specification reference covers what a two-component record should show.

Laboratories deciding between this line and a single-sequence purchase can compare the two documentation positions on CJC-1295 vs CJC-1295 / Ipamorelin.

Handling conditions attach to the vial, not to either sequence considered on its own. A mixture inherits the strictest constraint of any component and does so silently, so stability information established for one sequence alone does not transfer to the blend. Store sealed lyophilised vials at 2–8 °C, protected from light and moisture, and equilibrate to room temperature before opening. Environmental guidance for UAE conditions is in the research peptide storage guide.

After reconstitution the same logic holds: what is in solution is the blend, and both sequences are exposed to the same hydrolysis, oxidation and freeze-thaw history. Log the diluent and the date against the blend lot number rather than against a component name. Volume and concentration decisions belong to a validated in vitro SOP and are not set out here.

Inventory notation is where blends most often fail an audit. Record the full catalogue string — both sequences, both masses, the no-DAC qualifier — rather than an abbreviation that drops the qualifier and hides the second component from whoever reads the row a year later.

This blend is not an approved medicine in the United Arab Emirates or anywhere else, and it is not supplied for human or veterinary use. Orders are accepted against a research-use declaration retained in the order record, and VaultLabs makes no statements about physiological, hormonal or performance outcomes.

Both component classes appear on the World Anti-Doping Agency prohibited list — growth hormone-releasing factors and their analogues, and growth hormone secretagogues — so a laboratory connected to athlete populations or anti-doping work should control and log this line accordingly.

GH secretagogue pathway models

Combined peptide blend stability

Analytical blend characterization

2–8 °C (sealed lyophilized)

Store sealed vials per product label and COA. Protect from contamination in laboratory workflows.

Use within institutional SOP timelines after opening. Document preparation date for audit trails.